Chapter 11: Common Skin Complaints

Welcome to Last Minute Lecture.

This free chapter overview is designed to help students review and understand key concepts.

These summaries supplement, not replace, the original textbook and may not be redistributed or resold.

For complete coverage, always consult the official text.

Imagine a patient walks into your clinic complaining of just a severe full body itch.

Right.

You examine them from head to toe.

There's no rash.

No bug bites.

I mean, their skin looks perfectly high.

Completely normal on the surface.

Exactly.

So,

you might be tempted to just prescribe a heavy moisturizing lotion and send them right home.

Which is what a lot of people do.

But if you do that,

you might just miss a primary presentation of Hodgkin's lymphoma.

Yeah, that is a sobering thought.

It really is.

Welcome to this custom tailored deep dive.

If you're an advanced practice nursing student listening to this right now, maybe you're

Or, you know, staring down a massive exam on Chapter 11.

Common skin complaints.

Yes, common skin complaints.

You are in exactly the right place.

Consider this session your ultimate one -on -one tutoring guide.

And that is our singular mission today.

We are not just going to like read off a list of dermatological conditions for you to memorize.

No, because memorization totally fades under pressure.

Exactly.

What builds lasting clinical reasoning is understanding the foundational pathophysiology.

Tracing that logical flow.

Right.

Tracing it right through physical assessment,

narrowing down your differential diagnosis, and then building a safe evidence -based management plan.

So the skin is the body's largest, most visible organ.

And we often treat it like, I don't know,

a simple protective armor.

Like wrapping paper.

Right.

But it's profoundly interactive.

It serves as this real -time diagnostic display screen for underlying systemic disease.

It really does.

And to understand how that display screen works, we need to start at the very top of the head with the foundations of hair loss or alopecia.

Because to understand why hair falls out, you first have to understand the exact mechanisms of how it grows.

Yeah, the pathophysiology.

Right.

And understanding the growth cycle is critical because the medications you'll eventually prescribe will target very specific phases of this process.

Okay, so walk us through it.

So there are four continuous cycles of scalp hair growth.

First is the antigen phase.

The active growth phase, right?

Exactly.

It's characterized by really rapid cellular division in the hair bulb.

It's the longest phase lasting anywhere from two to six years.

Wow.

Up to six years.

Yeah.

At any given moment, about 90 to 95 % of the hair on a healthy scalp is actively growing in this antigen phase.

Okay, so what's next?

Next is the catagen phase.

This is a brief involution period lasting just two to three weeks.

And that's when it disconnects.

The follicle begins to shrink and literally detach from its blood supply.

Then comes the pelagen phase.

Which is like a resting period.

Exactly.

A resting period of about two to three months.

And finally, the exogen phase, which is the actual shedding of the hair shaft.

So think of the hair follicles like a massive manufacturing plant.

I love this analogy.

Right.

So the antigen phase is when the factory is running three shifts, rapidly turning out product.

Constantly working.

And then the catagen phase hits management, decides to downsize, and the heavy machinery starts powering down.

Telogen is when the remaining workers go on a long hiatus, leaving the factory totally quiet.

And exogen.

Exogen is simply clearing the old inventory out the back door so the whole manufacturing process can reset and start over.

That perfectly illustrates the physiology and, you know, it sets up our understanding of the most common cause of permanent hair loss.

Androgenic alopecia.

Or AGA.

All right.

Patients will almost always refer to this as male pattern baldness.

Sure.

But as a clinician, you need to understand the underlying science, starting with genetics.

Because there is a huge myth out there that you only inherit baldness from your mother's side.

Oh, totally a myth.

The clinical reality is that androgenic alopecia has a polygenic inheritance pattern.

Meaning multiple genes.

Right.

The genetic predisposition comes from both parents and affects both sexes across all ethnicities.

Yeah.

And the primary physiological drivers here are androgens.

Specifically, there's this enzyme 5 -alpha reductase.

Okay.

It converts circulating testosterone into its highly active metabolite, which is dihydrotestosterone, or DHT.

DHT.

Got it.

During puberty, DHT causes hair follicles on the chest or the face to grow larger and thicker.

But on the scalp… It does the exact opposite, right?

Exactly.

DHT binds to the receptors on the scalp and triggers miniaturization.

So it shrinks them.

The antigen phase shortens drastically, and the hair follicles literally shrink over time until they produce only these fine, almost invisible hairs.

So when you have a patient sitting in the exam room complaining of alopecia, you immediately arrive at this major differential fork in the road.

You have to make a choice.

Right.

You must determine is this alopecia scarring, meaning it's permanent, or is it non -starring, meaning it's potentially reversible.

And this is where your physical assessment skills are really tested.

What are we looking for?

You differentiate these two categories by looking closely at the scalp for visible follicular openings.

The pores.

Okay, so if it's non -scarring… In non -scarring alopecia, the scalp texture and color look completely normal, and you can clearly see those little follicular openings where the hair should be.

But if it's scarring?

If the scalp is atrophied, shiny, smooth, and there are absolutely zero visible follicular openings, you're looking at scarring or cicatricial alopecia.

The follicles are just gone.

Right.

They've been destroyed and replaced by fibrous tissue.

That hair loss is permanent.

Let's focus on the non -scarring types for a second, specifically alopecia areata.

Which is an autoimmune condition.

Right.

Where the body's immune system attacks the hair follicles.

If you look closely at the periphery of the bald patches with a magnifying lens, you'll often see these short, stubby hairs with tapered ends near the scalp.

They literally look like exclamation point hairs.

Yeah.

Exclamation point hairs, that's a great visual.

They are the classic visual hallmark of alopecia areata, but a comprehensive APN assessment doesn't stop at the scalp.

Where else are we looking?

If you also need to examine the patient's nails, you're looking for fine pitting on the dorsal nail plate that looks almost like hammered brass.

Hammered brass?

Yeah.

Because the nails and hair share similar keratinized matrices,

that hammered brass appearance is Another really strong clinical clue pointing toward a systemic autoimmune etiology.

Okay, so that brings us to building a patient -centered, evidence -based management plan.

The fun part.

Let's evaluate the pharmacological interventions for alopecia, starting with oral finasteride.

So finasteride works precisely on that pathophysiology we just discussed.

It competitively blocks 5 -alpha reductase.

Which halts the conversion of testosterone into that follicle -shrinking DHT.

Exactly.

But wait, if this medication functions as a systemic androgen blocker, prescribing it to a female patient experiencing hair loss seems like it would trigger a massive clinical red flag.

Oh, it is an absolute undeniable red flag, and it's an essential scope of practice boundary to recognize.

Why is it so dangerous?

Finasteride is highly teratogenic.

Because it blocks DHT, which is totally essential for normal male fetal development,

it causes severe abnormalities of the external genitalia in male fetuses.

Therefore, it is strictly contraindicated in women of reproductive age.

In fact, it's FDA approved for use in men only.

Good to know.

Furthermore, clinical evidence shows that finasteride is significantly less effective in men over the age of 60.

Why is that?

The reason is physiological.

As men age, their natural 5 -alpha reductase activity decreases anyway, so there's simply less of the enzyme for the drug to block.

Makes total sense.

So let's move to a topical option, like minoxidil.

Which is available over the counter.

Right.

And it's widely used for both men and women.

For women, the 2 % liquid solution is generally prescribed to be applied twice a day.

But there's a catch with compliance.

Yeah.

Clinical practice guidelines point out a huge compliance strategy here.

There's a 5 % minoxidil foam that only needs to be applied once a day.

And that makes a massive difference.

It really does.

Prescribing that once -daily 5 % foam drastically improves patient compliance and reported satisfaction.

Because of the irritation, right?

Exactly.

The liquid formulations often contain a lipid vehicle like propylene glycol that causes severe scalp irritation, which the foam largely avoids.

And reducing the burden of treatment is just a core principle of advanced practice.

Definitely.

Now, if you have a patient over 10 years old with limited areas of non -scarring hair loss, typically less than 50 % of the scalp -affected procedural interventions become your first -line treatment.

Like injections?

Specifically, intralesional corticosteroid injections.

You inject small amounts of trimacinolone acetonide directly into the mid -dermal layer of the bald patches.

Why the mid -dermal layer?

Because that is a precise anatomical depth where the localized inflammation is occurring right around the hair bulb.

These injections are spaced about a centimeter apart and repeated every four to six weeks.

Okay, so we just spent a lot of time looking at how local cellular changes affect hair follicles.

Let's shift our focus to how cellular behavior dictates the skin itself.

Moving on to the melanocytes.

Yes, specifically the melanocytes, and exploring pigmentation variations and pathologies.

So, the color of our skin is determined by melanin, which is produced by cells called melanocytes located in the basal layer of the epidermis.

Right.

But here is the foundational pathophysiology that governs everything else.

All humans, regardless of ethnicity, have roughly the exact same number of melanocytes.

Wait, really?

The same number?

The exact same number.

The vast differences in human skin color do not come from the number of the cells.

The difference comes from the size, the density, and the retention of the melanosomes.

Which are the tiny melanin -containing packets inside those cells.

Solstice.

So, larger, more densely packed melanosomes equal darker skin.

Exactly.

And this physiological difference has a profound impact on health promotion and risk assessment.

How so?

Those larger, more numerous melanosomes in darker skin act as a highly effective natural sun protection factor.

An SPF of roughly 5 to 13.

That's amazing.

Yeah, because this built -in melanin absorbs and scatters UV radiation before it can cause cellular DNA damage, the incidence of non -melanoma skin cancers, like basal cell carcinoma, is exceptionally rare in African -American patients.

Which leads to a really critical assessment scenario.

When you're examining a patient with darker skin,

distinguishing between a normal anatomical pigmentation variation and an actual pathology requires vital context.

Context is everything.

For example, oral hyperpigmentation like dark bluish -black or brown patches on the gingivet or the gums is a completely normal physiological variant in patients with dark skin or of African descent.

Totally normal.

But there is one absolute exception.

Oral hyperpigmentation should never be present in newborn infants.

That's a huge red flag.

If you identify this in a newborn, it requires immediate further investigation for underlying congenital or systemic syndromes.

Context determines pathology.

Let's look at conditions where pigmentation changes are definitively pathological, starting with vitiligo.

The autoimmune condition.

Right.

It's where the body selectively destroys melanocytes, resulting in total loss of skin color in patchy areas, creating these stark white macules.

And this is where a really vital piece of diagnostic hardware comes into play.

The woodslamp.

I love the woodslamp.

If you shine a woodslamp on a patch of vitiligo in a darkened room, the affected area will emit a bright, well -demarcated blue -white fluorescence.

And the physics behind that is just fascinating.

Oh, yeah.

Yeah.

So melanin normally absorbs UV light.

When the melanocytes are destroyed in vitiligo, there's no melanin left to absorb the light from the woodslamp.

So what happens to the light?

The UV light penetrates straight down to the dermal collagen, and it's the collagen itself that naturally fluoresces that stark blue -white color.

Oh, wow.

Once you confirm the diagnosis, management often involves topical corticosteroids to suppress the local autoimmune response.

But safety is paramount here.

What's the protocol?

You must explicitly instruct the patient to cycle these steroids, typically one week on and one week off.

To prevent thinning.

Exactly.

Continuous, uninterrupted use of topical corticosteroids disrupts collagen synthesis, leading to severe skin atrophy or thinning, and permanent striae, which are stretch marks.

Let's look at the pathological flip side, hyperpigmentation, specifically melasma, frequently referred to as the mask of pregnancy.

Right.

Melasma presents as symmetrical, irregular hyperpigmentation on sun -exposed areas like the cheeks, upper lip, and forehead.

What drives it?

Its pathophysiology is heavily influenced by a combination of hormonal surges, such as estrogen and progesterone during pregnancy, or from oral contraceptive use and direct UV sun exposure.

Okay, so the first line of pharmacological management for melasma is triple combination cream, or NTCC.

Which is a powerhouse.

It is.

This utilizes hydroquinone to block new melanin production, a retinoid to increase cellular turnover and shed the pigmented cells, and a corticosteroid to reduce localized inflammation.

But you can't just rely on the cream.

No, you must also aggressively advise the use of sunblock, specifically recommending iron oxide sunblock, because iron oxide blocks visible light in addition to UV radiation.

That's a great clinical pearl.

But there's a massive clinical warning regarding patients attempting to treat hyperpigmentation independently.

Oh, right, the over -the -counter stuff.

You must actively warn your patients about the extreme dangers of over -the -counter or imported skin bleaching and lightening creams.

Why?

What's in them?

Many of these unregulated products contain dangerously high levels of heavy metals, including mercury or really potent unbuffered hydroquinone.

That sounds incredibly toxic.

It is.

Prolonged use can cause systemic toxicity, renal damage, and this paradoxical, irreversible darkening of the skin known as exogenous okrinosis.

So always ask what topicals they're applying at home.

Always.

Now, before we transition away from pigmentation, we have to reinforce the ultimate priority setting for skin cancer.

The ABCDE mnemonic.

Yes.

When assessing pigmented neme or moles, the ABCDE mnemonic is your foundational red flag assessment tool.

A is for asymmetry.

One half of the lesion does not match the other.

B is for border irregularity.

The edges are ragged, notched, or blurred.

What about C?

C is for color variegation.

The presence of multiple shades like blue, gray, white, or uneven browns is a highly suspicious sign of malignant transformation.

And D?

D is for diameter greater than 6 millimeters, which is roughly the size of a pencil eraser.

And E is for evolving, meaning the lesion is actively changing in size, shape, color, or elevation over time.

Let's transition from visible pigmentation to an entirely invisible symptom.

Pruritus.

Exactly.

Sometimes the skin looks completely normal.

There are no changing moles, no lost pigment, no visible lesions.

But the patient is absolutely miserable from pruritus or severe itching.

And pruritus is perceived by the nervous system as incredibly unpleasant, often severe enough to disrupt the sleep cycle, and severely impaired daily cognitive functioning.

Here is where clinical instincts are truly tested.

If a patient presents with an intense, full -body itch, but there are zero visual signs.

Is that at all?

No rash, no erythema, absolutely nothing visible on the skin.

My first instinct as a clinician is to assume severe dry skin.

Grab a heavy emollient, prescribe a moisturizer, and send them home.

Why wouldn't I just do that?

Because treating the surface without investigating the cause is exactly how critical diagnoses are missed.

Right.

Pruritus without a primary skin rash is a massive red flag for underlying systemic disease.

If the skin is clear, but the itch is severe and generalized, it must trigger a comprehensive diagnostic workup.

What are we ordering?

You need to order a CBC, an ESR for systemic inflammation, a TSH for thyroid function, liver function tests, and a comprehensive renal profile.

So the invisible itch is really trying to tell you a deeper physiological story.

Exactly.

For instance, chronic renal failure causes uremic toxins to build up in the bloodstream and deposit in the skin,

causing severe itching that often requires UV therapy to manage.

Wow.

Colostasis forces bile salts into the dermal layers.

Hypothyroidism decreases sebum production, drawing the skin from the inside out.

And there's a malignancy connection too, right?

Yes.

Most alarmingly, generalized pruritus can be an early primary presentation of malignancy.

Approximately 35 % of Hodgkin's lymphoma cases feature severe generalized pruritus due to a massive systemic release of inflammatory cytokines.

35%.

That is huge.

While you are actively working up that systemic cause, you still have to manage the symptom so the patient doesn't inflict excoriation injuries on themselves.

Yes.

Symptom management is key.

For severe dry skin or cirrhosis, which profoundly exacerbates itching, especially in the geriatric population, the recommended non -pharmacologic management is the soak and smear technique.

The mechanism here is simple but highly effective.

How does it work?

Have the patient soak in lukewarm water for 20 minutes to hydrate the stratum corneum.

Then, they get out, lightly pat dry, and immediately smear a heavy petrolatum -based ointment all over their body.

Ointment, not lotion, right?

You must use ointments, not lotions.

Lotions have a high water content that quickly evaporates, pulling more moisture out of the skin.

Petrolatum creates an occlusive seal that physically traps the hydration in the tissue.

For pharmacologic symptom management, antihistamines are the standard.

But selection definitely matters here.

Absolutely.

For daytime use, you require non -sedating second -generation antihistamines like fexofenadine.

If the pruritus is destroying their sleep architecture,

prescribing a sedating first -generation antihistamine like hydroxazine at night can be incredibly effective.

And there is also a vital safety consideration regarding localized antigenital pruritus.

Oh, right.

You can safely prescribe pramoxane cream, which is a topical anesthetic.

But… But you must strictly avoid prescribing potent,

fluorinated topical steroids in the antigenital region.

That is a critical pharmacological safety point.

The stratum corneum in the antigenital area is exceptionally thin and naturally occluded by skin folds and clothing.

So absorption is through the roof.

Because of this, fluorinated steroids are far too potent.

They will cause rapid, severe, and permanent tissue atrophy and striae in a highly sensitive region.

Alright.

When the itch does present with a visible skin eruption, we enter the territory of rashes.

And to understand the clinical management of a rash, we have to examine the epidermal barrier itself.

Right.

The outermost layer of the epidermis is the stratum corneum.

It's composed of roughly 25 layers of tightly packed, dead cells completely filled with a tough, fibrous protein called keratin.

And this structure makes your skin highly impermeable.

It keeps essential hydration trapped inside, and it keeps environmental microbes and chemicals outside.

Think of the stratum corneum like a high -tech waterproof jacket.

It's your ultimate defensive barrier.

But when a rash develops, there's underlying cellular inflammation.

The integrity of that waterproof jacket gets torn.

Right.

The skin suddenly becomes highly permeable.

And this structural breakdown leads to a major safety warning for prescribing APNs.

What's the warning?

Because that barrier is compromised and inflamed, any therapeutic topical cream or ointment you apply to a rash will be absorbed much faster and in much higher systemic quantities than it would be on healthy, intact skin.

So there's a risk of toxicity.

This dramatically increases the risk of systemic toxicity and adverse effects, such as adrenal suppression from topical corticosteroids.

You have to adjust your dosing and potency with that increased physiological permeability in mind.

That structural reality also impacts physical assessment, particularly in patients with darker skin tones.

Standard clinical training often emphasizes looking for erythema, or pink and red eruptions, to identify inflammation.

And that specific visual bias frequently leads to missed or delayed diagnoses.

How does it present differently?

In melanin -rich skin, the typical red or pink vasodilation of a rash is often completely masked.

Instead, the inflamed area may appear dark, brown, gray, or violaceous.

So you can't just rely on color.

As a clinician, you cannot rely on visual color cues alone.

You must train your hands to feel the skin.

Tactile assessment.

Rely heavily on the history of the lesion.

Its tactile texture.

Is there subtle warmth?

Is it indurated?

Is it rough or scaling?

And carefully map its distribution pattern on the body.

Speaking of critical diagnostic distinctions, there is a severe red flag diagnosis regarding rashes that every APN must recognize.

Mamory -Paget's disease.

This is a crucial one.

Mamory -Paget's disease is a rare form of breast cancer where malignant cells extend from the underlying ductal tissue up into the epidermis.

That looks very innocent, right?

It presents as a scaling erythematous plaque that looks exactly like common eczema localized on the nipple and the areola.

So how do you clinically differentiate between benign eczema and underlying carcinoma?

Clinical reasoning and precise timing.

Eczema typically affects both breasts simultaneously and will show rapid improvement with a short course of mild topical corticosteroids.

But Paget's is different.

Mamory -Paget's disease is almost exclusively unilateral affecting only one breast.

The clinical rule is absolute.

If you evaluate a unilateral eczema -like eruption on the nipple that does not completely resolve after two weeks of targeted topical corticosteroid treatment, you must suspect an underlying malignancy.

And refer them.

You refer that patient to an oncology or breast specialist immediately.

Continuing to prescribe steroids will only delay a life -saving diagnosis.

For our final segment, we are going to look at a specific, rapidly shifting presentation.

Urticaria or hives?

Urticaria is characterized by intensely pruritic wheels caused by the rapid degranulation of mast cells and the subsequent release of histamine.

They move around, right?

Yes.

These wheels appear, enlarge, coalesce, and then spontaneously resolve, usually within 24 hours, only to erupt in a different anatomical location.

These presentations are divided into two main categories.

There's chronic spontaneous urticaria, which persists longer than six weeks and often lacks a clear identifiable trigger.

Right.

And then there's chronic inducible urticaria, which is triggered by specific external physical stimuli.

Inducible urticaria is directly provoked by physical forces like cold, heat, or sustained pressure.

A classic example is dermatographism.

What exactly is dermatographism?

It's where applying firm pressure, scratching, or stroking the skin produces a raised linear wheel due to the mechanical shearing forces triggering those localized mast cells.

Fascinating.

Now, there's a specialized presentation of urticaria regarding pregnancy known as PUPPP, or Puritic Urticarial Papules and Plaques of Pregnancy.

PUPPP is a benign but intensely puritic eruption that typically originates directly on the abdominal stria, the stretch marks, during the third trimester, where the connective tissue is undergoing rapid micro tearing.

And it spreads from there.

It frequently spreads to the thighs and buttocks.

Clinical data indicates that risk factors include being pregnant with a male fetus, experiencing a first pregnancy, or carrying multiple gestations.

Safely managing a pregnant patient with PUPPP requires careful pharmacological selection.

It's a delicate balance.

The first line evidence -based treatment relies on moderate to high potency topical steroids to control the localized inflammation.

If oral medication is required to manage severe systemic itching, you really have to weigh the risks carefully.

Right, because no medication is perfectly without risk during pregnancy.

Exactly.

But diffenhydramine, which is a first generation antihistamine, is generally considered the safest oral option due to its extensive historical safety track record.

And what about second generation?

Second generation antihistamines should be utilized only at the lowest possible effective dose and for the shortest necessary duration.

To structure clinical management for all forms of urticaria, clinical guidelines utilize a precise stepwise algorithm, illustrated in figure 11 .1.

Let's trace how an APN student should think through these pharmacological escalations.

It's a logical progression designed to maximize symptom control while minimizing side effects.

Step one is your baseline intervention.

You initiate treatment with over -the -counter second generation non -sedating H1 antihistamines such as fexofenadine or siderazine alongside strict avoidance of any known triggers.

Got it.

But if the patient returns reporting that step one is failing to control the wheels, you escalate to step two.

Step two requires aggressive receptor blockade.

You can incrementally titrate the dose of that second generation antihistamine up to Four times the standard recommended dose to fully saturate the H1 receptors.

Four times the dose.

Alternatively, you can layer therapies by adding a different second generation drug, adding an H2 receptor antagonist, adding a leukotrine receptor antagonist, or introducing a sedating first generation antihistamine specifically at bedtime to ensure sleep.

Makes sense.

If the pruritus and wheels remain refractory to that aggressive titration, you move to step three.

Step three involves escalating to a higher, more potent dose of a first generation H1 antihistamine around the clock.

At this stage, you're utilizing the heavy pharmacological hitters, and the patient must accept that profound sedation will be an unavoidable side effect.

Finally, step four is reserved for the most recalcitrant severe cases.

In step four, you transition to advanced systemic therapies.

This includes immunosuppressants like cyclosporine, which suppress the underlying T -cell activity, or biologic agents like omalizumab, which specifically binds to free IgE in the bloodstream to prevent mast cell activation.

Are systemic steroids used here?

You may also utilize short, targeted bursts of systemic corticosteroids at this stage, but treatment must be strictly limited to less than three weeks to prevent severe metabolic side effects or an adrenal crisis.

We have covered massive clinical ground today.

We traced the cellular physiology of the hair cycle to understand finasteride's turechenic risks.

We explored how melanosome density dictates ultraviolet protection.

Uncovered the systemic malignancies hiding behind a rash -free itch.

And navigated the exact pharmacological algorithm for suppressing urticaria.

When you anchor this vast amount of clinical data to the underlying pathophysiology and prioritize patient safety, it transforms from a daunting list of facts into a clear, reliable roadmap for advanced practice reasoning.

I want to leave you with a final shift in perspective to carry into your exams and your clinical rotations.

In primary care, it's easy to treat the skin like it's just the body's wrapping paper.

A static surface to be moisturized, injected, or covered up with a steroid cream.

But consider the reality of what we just explored.

Exactly.

The gut microbiome is currently being researched as a major causative factor and future treatment target for autoimmune alopecia.

The endocrine system directly paints the skin through hormonal melasma.

And a completely invisible itch can be the very first alarm bell of a hematologic cancer.

It's all connected.

The skin is a dynamic, fully integrated diagnostic display screen.

So the next time a patient walks into your clinic complaining about a simple rash or a stubborn itch, what is their skin really trying to tell you?

Cultivating the instinct to ask that question is exactly what separates a good student from a great clinician.

Thank you so much for joining us for this session.

From the Last Minute Lecture Team, we believe in you, we are rooting for your success, and we wish you the absolute best in your continued APN studies.

Keep diving deep.